pd1 Is Pembrolizumab Keytruda?

Pembrolizumab is a PD-1 (programmed death-1) inhibitor. By blocking the binding of PD-1 to its ligand PD-L1, it relieves cancer cells from inhibiting the attack of immune cells, thereby enhancing the body's immune system's ability to attack cancer cells. Pembrolizumab is a targeted (biological) therapy, which is also called immunotherapy. Pembrolizumab is the off-brand name of the drug. Its trade name is Keytruda, and its domestic Chinese name is Keytruda. Pembrolizumab can be used together with chemotherapy or alone. It has been approved in many countries for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, lymphoma, etc.